Skip to main content
. 2022 Jan 27;40(11):1155–1162. doi: 10.1200/JCO.21.02742

FIG 2.

FIG 2.

CONSORT diagram showing the enrollment of subjects, their allocation to each cohort, Ki-67 status and treatment arm, and how they are analyzed in the monarchE trial. aIncorrect cohort assignment. ET, endocrine therapy; FDA, US Food and Drug Administration; ITT, intent-to-treat; NA, not applicable; NE, not evaluable.